DO-1

About DeuterOncology

DeuterOncology is a private, clinical-stage biotechnology company leveraging deuteration chemistry to develop improved kinase inhibitors. Its lead asset, DO-2, is a deuterated, brain-penetrant MET/RAS pathway inhibitor currently in Phase I dose expansion for MET-altered solid tumors, with preliminary data showing promising safety and activity. The company, founded by Dr. Timothy Perera, has secured Series A financing and grant funding to advance its pipeline, aiming to establish a best-in-class therapy in the competitive MET inhibitor landscape.

Therapeutic Areas

Other Not specified Drugs